Prescription Drug Provisions in the Inflation Reduction Act of 2022 | Wilson Sonsini Goodrich & Rosati

The Inflation Reduction Act of 2022 (the Act) includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, such...

Related Keywords

White House ,District Of Columbia ,United States ,Wilson Sonsini Goodrich Rosati ,America Ph ,Centers For Medicare Medicaid Services ,Service Fees ,Coverage Gap Discount Program ,Us Department Of Health ,Human Services ,Office Of Inspector ,Children Health Insurance Program ,Drug Administration ,Insulin Products ,Wilson Sonsini Goodrich ,Inflation Reduction Act ,Pharmaceutical Research ,Medicaid Services ,Price Negotiation ,Certain High Priced Single Source Medicare ,Delay Selection ,Biosimilar Entry ,Excise Tax ,Partd Drugs ,Limited Exceptions ,Average Sales Price ,Average Manufacturer Price ,Prescription Drug Rebate Rule Until ,Anti Kickback Statute ,Inspector General ,Safe Harbor Protection ,Rebates Involving Prescription Pharmaceuticals ,New Safe Harbor Protection ,Certain Point Of Sale Reductions ,Prescription Pharmaceuticals ,Certain Pharmacy Benefit Manager Service ,Partd Redesign ,Covered Insulin Products Limited ,Medicare Partb Add On Payments ,Adult Vaccines Under Part ,Health Insurance ,Briefing Room ,Press Release ,Inflation Reduction Act Becoming Law ,